sponsored
PatientsVille.com Logo

PatientsVille

Argininosuccinate Medical Research Studies

Up-to-date List of Argininosuccinate Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Argininosuccinate Medical Research Studies

Rank Status Study
1 Recruiting Nitric Oxide Supplementation in Argininosuccinic Aciduria
Conditions: Argininosuccinic Aciduria;   Argininosuccinate Lyase Deficiency;   Urea Cycle Disorders
Interventions: Dietary Supplement: Nitric oxide supplement;   Dietary Supplement: Placebo
Outcome Measure: Vascular endothelial function as assessed by FMD of brachial artery
2 Recruiting Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)
Condition: Urea Cycle Disorder
Intervention:
Outcome Measure: Assessment of UCD specific disease characteristics
3 Recruiting Ph 1 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies
Condition: Advanced Gastrointestinal (GI) Malignancies
Intervention: Drug: ADI-PEG 20
Outcome Measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies.
4 Recruiting Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
Condition: Advanced Pancreatic Cancer
Intervention: Drug: ADI-PEG 20
Outcome Measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer
5 Recruiting Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Conditions: Pleural Mesothelioma Malignant Advanced;   Peritoneal Mesothelioma Malignant Advanced;   Non-squamous Non-small Cell Lung Carcinoma Stage IIIB/IV (NSCLC);   Metastatic Uveal Melanoma;   Hepatocellular Carcinoma (HCC);   Glioma
Intervention: Drug: ADI-PEG 20
Outcome Measures: Define initial estimates of efficacy, measured by RECIST 1.1 criteria for non-squamous NSCLC, advanced peritoneal mesothelioma, metastatic uveal melanoma, HCC and glioma for ADI-PEG 20 in combination with pemetrexed and cisplatin.;   Define initial estimates of efficacy, measured by modified RECIST criteria for advanced MPM;   Determine the MTD of ADI-PEG 20 in combination with pemetrexed and cisplatin
6 Recruiting PH 2 ADI-PEG 20 Acute Myeloid Leukemia
Condition: AML Subjects Who Have Failed Prior Systemic Therapy
Intervention: Drug: ADI-PEG 20
Outcome Measures: Response Rate;   Safety and tolerability
7 Recruiting Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Condition: Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Intervention: Drug: ADI-PEG 20
Outcome Measures: Number of participants with adverse events.;   Number of participants with objective responses.

These studies may lead to new treatments and are adding insight into Argininosuccinate etiology and treatment.

A major focus of Argininosuccinate research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Argininosuccinate